Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ.DE) • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold EUZ.DE in your mock portfolio yet.
With a PE ratio of 19.70 and EPS of €0.79, Eckert & Ziegler is valued at a moderate earnings multiple that suggests neither deep distress nor high-growth expectations. The valuation implies the market sees the company as reasonably profitable and relatively stable, but not a high‑momentum growth story. In the absence of detailed revenue and margin trends, the current metrics point to steady but unspectacular financial performance.
The stock trades at €15.56, only slightly below its 200‑day moving average of €15.65, and is up 3.6% over the last month, suggesting a mild short‑term positive trend but no clear breakout. An RSI of 51.97 is almost exactly neutral, indicating neither overbought nor oversold conditions. Overall, technicals point to a consolidating stock with balanced upside and downside risks in the near term.
Alternative data show limited digital traction and softening hiring activity. Web traffic at roughly 27,887 monthly visitors is modest, and social media followings across Twitter/X, Instagram, and YouTube are small with minimal recent growth, suggesting low brand engagement and limited marketing reach. A 25% month‑over‑month decline in job openings points to a cautious hiring stance that may reflect management conservatism on near‑term growth.
Overall sentiment on Eckert & Ziegler Strahlen- und Medizintechnik AG is neutral. Financial metrics and valuation look reasonable but do not clearly point to accelerating growth, while technicals show a stock consolidating around its long‑term average. Weak alternative data signals, especially the drop in job postings and muted digital engagement, temper the outlook and argue for a cautious stance until clearer growth or momentum catalysts emerge.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started